Drug delivery systems for vitreoretinal diseases

Progress in Retinal and Eye Research

Volumn 23, Issue 3, 2004, Pages 253-281

  Yasukawa, Tsutomu ^a,b   Ogura, Yuichiro ^c   Tabata, Yasuhiko ^d   Kimura, Hideya ^e   Wiedemann, Peter ^a   Honda, Yoshihito ^b,f  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b KYOTO UNIVERSITY   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e Nagata Eye Clinic   (Japan)

^f OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTIGEN; ANTIVIRUS AGENT; APTAMER; BETAMETHASONE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETHYLENE VINYL ACETATE COPOLYMER; FLUCONAZOLE; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FLUOROURIDINE; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; MICROSPHERE; MITOMYCIN C; POLYANHYDRIDE; POLYMER; POLYVINYL ALCOHOL; PROTEINASE INHIBITOR; SEBACIC ACID; SILICONE DERIVATIVE; STEROID; THALIDOMIDE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

BIODEGRADABLE IMPLANT; BONE MARROW SUPPRESSION; CATARACT; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOPHTHALMITIS; HUMAN; IONTOPHORESIS; KIDNEY DYSFUNCTION; MOLECULAR WEIGHT; PRIORITY JOURNAL; RETINA DETACHMENT; RETINITIS; REVIEW; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

ABSORBABLE IMPLANTS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE DISEASES; HUMANS; LIPOSOMES; MICROSPHERES; PHARMACEUTICAL PREPARATIONS; RETINAL DISEASES; VITREOUS BODY;

EID: 2942536634     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2004.02.003     Document Type: Review

References (186)

1. Aihara M., Lindsey J.D., Weinreb R.N. Enhanced FGF-2 movement through human sclera after exposure to latanoprost. Invest. Ophthalmol. Vis. Sci. 42:2001;2554-2559
2. Ambati J., Adamis A.P. Transscleral drug delivery to the retina and choroid. Prog. Retin. Eye Res. 21:2002;145-151
3. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., Kim I., Delori F.C., Adamis A.P. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41:2000;1181-1185
4. Ambati J., Gragoudas E.S., Miller J.W., You T.T., Miyamoto K., Delori F.C., Adamis A.P. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41:2000;1186-1191
5. Ambati J., Ambati B.K., Yoo S.H., Ianchulev S., Adamis A.P. Age-related macular degeneration. etiology, pathogenesis, and therapeutic strategies Surv. Ophthalmol. 48:2003;257-293
6. American Academy of Ophthalmology, 2000. Photodynamic therapy with verteporfin for age-related macular degeneration. Ophthalmology 107, 2314-2317.
7. Armstrong D., Augustin A.J., Spengler R., Al-Jada A., Nickola T., Grus F., Koch F. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 212:1998;410-414
8. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., Katlama C., Debre P., Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116
9. Barza M., Peckman C., Baum J. Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology. 93:1986;133-139
10. Baum J., Peyman G.A., Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis, III. consensus Surv. Ophthalmol. 26:1982;204-206
11. Beckman J.S., Minor R.L., White C.W., Repine J.E., Rosen G.M., Freeman B.A. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J. Biol. Chem. 263:1988;6884-6892
12. Bendich A., Kafkewitz D., Abuchowski A., Davis F.F. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice. Clin. Exp. Immunol. 48:1982;273-278
13. Bochot A., Couvreur P., Fattal E. Intravitreal administration of antisense oligonucleotides. potential of liposomal delivery Prog. Retin. Eye Res. 19:2000;131-147
14. Bressler N.M. Submacular surgery. new information, more questions Arch. Ophthalmol. 115:1997;1071-1072
15. Burrows F.J., Thorpe P.E. Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol. Ther. 64:1994;155-174
16. Burrows F.J., Derbyshire E.J., Tazzari P.L., Amlot P., Gazdar A.F., King S.W., Letarte M., Vitetta E.S., Thorpe P.E. Up-regulation of endoglin on vascular endothelial cells in human solid tumors. implications for diagnosis and therapy Clin. Cancer Res. 1:1995;1623-1634
17. Cantrill W.H., Henry K., Melroe N.H., Knobloch W.H., Ramsey R.C., Balfour H.H. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. long-term results Ophthalmology. 96:1989;367-374
18. Canzano J.C., Reed J.B., Morse L.S. Vitreomacular traction syndrome following highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina. 18:1998;443-447
19. Carnemolla B., Balza E., Siri A., Zardi L., Nicotra M.R., Bigotti A., Natali P.G. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108:1989;1139-1148
20. Castronovo V., Belotti D. TNP-470 (AGM-1470). mechanisms of action and early clinical development Eur. J. Cancer. 32A:1996;2520-2527
21. Chakravarthy U., Houston R.F., Archer D.B. Treatment of age-related subfoveal neovascular membranes by teletherapy. Br. J. Ophthalmol. 77:1993;265-273
22. Cheng L., Hostetler K.Y., Chaidhawangul S., Gardner M.F., Beadle J.R., Keefe K.S., Bergeron-Lynn G., Severson G.M., Soules K.A., Mueller A.J., Freeman W.R. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest. Ophthalmol. Vis. Sci. 41:2000;1523-1532
23. Choi T.B., Lee D.A. Transscleral and transcorneal iontophoresis of vancomycin in rabbit eye. J. Ocul. Pharmacol. 4:1988;153-164
24. Church A.L., Barza M., Baum J. An improved apparatus for transscleral iontophoresis of gentamicin. Invest. Ophthalmol. Vis. Sci. 33:1992;3543-3545
25. Cocherau-Massin I., Lehoang P., Lautier-Frau M., Zazun L., Robinet M. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 98:1991;1348-1355
26. de Rojas Silva M.V., Rodriguez-Ares M.T., Sanchez-Salorio M., Lamas Diaz M.J., Cuevas Alvarez J., Vila Jato J.L., Capeans Tome C. Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 237:1999;840-847
27. Duncan R. Drug-polymer conjugates. potential for improved chemotherapy Anticancer Drugs. 3:1992;175-210
28. Dvorak H.F., Sioussat T.M., Brown L.F., Berse B., Nagy J.A., Sotrel A., Manseau E.J., Van de Water L., Senger D.R. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors. concentration in tumor blood vessels J. Exp. Med. 174:1991;1275-1278
29. Eckardt C., Eckardt U., Conrad H.G. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 237:1999;313-325
30. El-Ghrably I.A., Dua H.S., Orr G.M., Fischer D., Tighe P.J. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br. J. Ophthalmol. 85:2001;461-470
31. Elias D.J., Hirschowitz L., Kline L.E., Kroener J.F., Dillman R.O., Walker L.E., Robb J.A., Timms R.M. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunoconjugate in patients with non-small cell lung carcinoma. Cancer Res. 50:1990;4154-4159
32. Epenetos A.A., Snook D., Durbin H., Johnson P.M., Taylor-Papadimitriou J. Limitation of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46:1986;3183-3191
33. Folkman J. Angiogenesis research. from laboratory to clinic Forum (Genova). 9:1999;59-62
34. Friedlander M., Theesfeld C.L., Sugita M., Fruttiger M., Thomas M.A., Chang S., Cheresh D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA. 93:1996;9764-9769
35. Fundaro A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin. pharmacokinetics and tissue distribution after i.v. administration to rats Pharmacol. Res. 42:2000;337-343
36. Gaton D.D., Sagara T., Lindsey J.D., Gabelt B.T., Kaufman P.L., Weinreb R.N. Increased matrix metalloproteinases 1, 2 and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch. Ophthalmol. 119:2001;1165-1170
37. Geroski D.H., Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 52:2001;37-48
38. Giordano G.G., Refojo M.F., Arroyo M.H. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Vis. Sci. 34:1993;2743-2751
39. Giordano G.G., Chevez-Barrios P., Refojo M.D., Garcia C.A. Biodegradation and tissue reaction to intravitreous biodegradable poly(D, L-lactic-co- glycolic)acid microspheres. Curr. Eye Res. 14:1995;761-768
40. Gonzalez-Avila G., Lozano D., Manjarrez M.E., Ruiz V.M., Teran L., Vadillo-Ortega F., Selman M. Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy. Ophthalmology. 102:1995;1400-1405
41. Gross J.B., Bozzete S.A., Mathews W.C., Spector S.A., Abramson I.S., McCutchan J.A., Mendez T., Munguia D., Freeman W.R. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 97:1990;681-686
42. Grossman R., Lee D.A. Transscleral and transcorneal iontophoresis of ketoconazole in the rabbit eye. Ophthalmology. 96:1989;724-729
43. Hangai M., Kaneda Y., Tanihara H., Honda Y. In vivo gene transfer into the retina mediated by a novel liposome system. Invest. Ophthalmol. Vis. Sci. 37:1996;2678-2685
44. Harper C.A. 3rd, Khoobehi B., Peyman G.A., Gebhardt B.M., Dunlap W.A. Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits. Int. Ophthalmol. 17:1993;337-340
45. Hashizoe M., Ogura Y., Kimura H., Moritera T., Honda Y., Kyo M., Hyon S.H., Ikada Y. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch. Ophthalmol. 112:1994;1380-1384
46. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., Ikada Y. Biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr. Eye Res. 14:1995;473-477
47. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., Ikada Y. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr. Eye Res. 16:1997;633-639
48. Heinemann M.H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch. Ophthalmol. 107:1989;1767-1772
49. Henderly D.E., Freeman W.R., Causey D.M., Rao N.A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 94:1987;425-434
50. Hennis H.L., Scott A.A., Apple D.J. Cytomegalovirus retinitis. Surv. Ophthalmol. 34:1984;193-203
51. Herrero-Vanrell R., Refojo M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52:2001;5-16
52. Herrero-Vanrell R., Ramirez L., Fernandez-Carballido A., Refojo M.F. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm. Res. 17:2000;1323-1328
53. Hershfield M.S., Buckley R.H., Greenberg M.L., Melton A.L., Schiff R., Hatem C., Kurtzberg J., Markert M.L., Kobayashi R.H., Kobayashi A.L., et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med. 316:1987;589-596
54. Hinton D.R., He S., Jin M.L., Barron E., Ryan S.J. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye. 16:2002;422-428
55. Holland G.N., Pepose J.S., Pettit T.H., Gottlieb M.S., Yee R.D., Foos R.Y. Acquired immune deficiency syndrome. ocular manifestations Ophthalmology. 90:1983;859-873
56. Holland, G.N., Sakamoto, M.J., Hardy, D., Sidikaro, Y., Kreiger, A.E., Frenkel, L.M., The UCLA CMV Retinopathy Study Group, 1986. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxyl-1-(hydroxy-methyl)ethoxymethyl] guanine. Arch. Ophthalmol. 104, 1794-1800.
57. Hora M.S., Rana R.K., Nunberg J.H., Tice T.R., Gilley R.M., Hudson M.E. Release of human serum albumin from poly(lactide-co-glycolide) microspheres. Pharm. Res. 7:1990;1190-1194
58. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550
59. Hueber, A., Wiedemann, P., Esser, P., Heimann, K., 1996-1997. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int. Ophthalmol. 20, 345-350.
60. Ip M., Gorin M.B. Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am. J. Ophthalmol. 122:1996;594-595
61. Jabs D.A., Newman C., de Bustors S., Polk B.F. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology. 94:1987;824-830
62. Jabs D.A., Enger C., Bartlett F.G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 107:1989;75-80
63. Jaffe G.J., Yang C.S., Wang X.C., Cousins S.W., Gallemore R.P., Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 105:1998;46-56
64. Jaffe G.J., Ben-nun J., Guo H., Dunn J.P., Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 107:2000;2024-2033
65. Jaffe G.J., Pearson P.A., Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 20:2000;402-403
66. Jerdan J.A., Pepose J.S., Michels R.G., Hayashi H., de Bustros S., Sebag M., Glaser B.M. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology. 96:1989;801-810
67. Jonas J.B., Hayler J.K., Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br. J. Ophthalmol. 84:2000;1064-1067
68. Kamizuru H., Kimura H., Yasukawa T., Tabata Y., Honda Y., Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest. Ophthalmol. Vis. Sci. 42:2001;2664-2672
69. Kampik A., Kenyon K.R., Michels R.G., Green W.R., de la Cruz Z.C. Epiretinal and vitreous membranes. Comparative study of 56 cases. Arch. Ophthalmol. 99:1981;1445-1454
70. Kaplan H. Submacular surgery for choroidal neovascularization. Br. J. Ophthalmol. 80:1996;101
71. Kaplan H.J., Leibole M.A., Tezel T., Ferguson T.A. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 5:1999;292-297
72. Karavellas M.P., Plummer D.J., Macdonald J.C., Torriani F.J., Shufelt C.L., Azen S.P., Freeman W.R. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179:1999;697-700
73. Katre N.V., Knauf M.J., Laird W.J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA. 84:1987;1487-1491
74. Khoobehi B., Stadtmann M.O., Peyman G.A., Aly O.M. Clearance of fluorescein incorporated into microspheres from the cornea and aqueous after subconjunctival injection. Ophthalmic Surg. 21:1990;840-844
75. Khoobehi B., Stradtmann M.O., Peyman G.A., Aly O.M. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. 22:1991;175-180
76. Kim J.W., Lindsey J.D., Wang N., Weinreb R.N. Increased human scleral permeability with prostaglandin exposure. Invest. Ophthalmol. Vis. Sci. 42:2001;1514-1521
77. Kimura H., Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 215:2001;143-155
78. Kimura H., Ogura Y., Moritera T., Honda Y., Wada R., Hyon S.H., Ikada Y. Injectable microspheres with controlled drug release for glaucoma filtering surgery. Invest. Ophthalmol. Vis. Sci. 33:1992;3436-3441
79. Kimura H., Ogura Y., Hashizoe M., Nishiwaki H., Honda Y., Ikada Y. A new vitreal drug delivery system using an implantable biodegradable polymer device. Invest. Ophthalmol. Vis. Sci. 35:1994;2815-2819
80. Kimura H., Ogura Y., Moritera T., Honda Y., Tabata Y., Ikada Y. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr. Eye Res. 13:1994;353-360
81. Kimura H., Sakamoto T., Hinton D.R., Spee C., Ogura Y., Tabata Y., Ikada Y., Ryan S.J. A new model of subretinal neovascularization in the rabbit. Invest. Ophthalmol. Vis. Sci. 36:1995;2110-2119
82. Klein R., Klein B.E.K., Linton K.L.P. Prevalence of age-related maculopathy. the Beaver Dam Eye Study Ophthalmology. 99:1992;933-943
83. Kraling B.M., Razon M.J., Boon L.M., Zurakowski D., Seachord C., Darveau R.P., Mulliken J.B., Corless C.L., Bischoff J. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am. J. Pathol. 148:1996;1181-1191
84. Krishnan I.S., Hansen H.J., Losman M.J., Goldenberg D.M., Leung S.O. Chimerization of Mu-9. a colon-specific antigen-p antibody reactive with gastrointestinal carcinomas Cancer. 80:1997;2667-2674
85. Kunou N., Ogura Y., Hashizoe M., Honda Y., Hyon S.H., Ikada Y. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release. 37:1995;143-150
86. Kunou N., Ogura Y., Yasukawa T., Kimura H., Miyamoto H., Honda Y., Ikada Y. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release. 68:2000;263-271
87. Kusaka M., Sudo K., Matsutani E., Kozai Y., Marui S., Fujita T., Ingber D., Folkman J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer. 69:1994;212-216
88. La Heij E.C., van de Waarenburg M.P., Blaauwgeers H.G., Kessels A.G., Liem A.T., Theunissen C., Steinbusch H., Hendrikse F. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am. J. Ophthalmol. 134:2002;367-375
89. Lam T.T., Edward D.P., Zhu X.A., Tso M.O. Transscleral iontophoresis of dexamethasone. Arch. Ophthalmol. 107:1989;1368-1371
90. Lam T.T., Fu J., Tso M.O. A histopathologic study of retinal lesions inflicted by transscleral iontophoresis. Graefes Arch. Clin. Exp. Ophthalmol. 229:1991;389-394
91. Lam T.T., Fu J., Chu R., Stojack K., Siew E., Tso M.O. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis. J. Ocul. Pharmacol. 10:1994;571-575
92. Lang L.C. Ocular drug delivery. conventional ocular formulations Adv. Drug Deliv. Rev. 16:1995;39-43
93. Lee J., Cho E.C., Cho K. Incorporation and release behavior of hydrophobic drug in functionalized poly(D, L-lactide)-block-poly(ethylene oxide) micelles. J. Control. Release. 94:2004;323-335
94. Lim J.I., Wolitz R.A., Dowling A.H., Bloom H.R., Irvine A.R., Schwarz D.M. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 127:1999;288-293
95. Machemer R., Laqua H. Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am. J. Ophthalmol. 80:1975;1-23
96. Macular Photocoagulation Study Group, 1986. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch. Ophthalmol. 104, 503-512.
97. Macular Photocoagulation Study Group, 1990. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch. Ophthalmol. 108, 825-831.
98. Macular Photocoagulation Study Group, 1994a. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch. Ophthalmol. 112, 480-488.
99. Macular Photocoagulation Study Group, 1994b. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch. Ophthalmol. 112, 500-509.
100. Maguire M.G., Fine S.L., Maguire A.M., D'Amato R.J., Singerman L.J. Results of the age-related macular degeneration and thalidomide study (AMDATS). Invest. Ophthalmol. Vis. Sci. 42:2001;S233
101. Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog. Lipid Res. 41:2002;392-406
102. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy. mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46:1986;6387-6392
103. Maurice D.M. Iontophoresis of fluorescein into the posterior segment of the rabbit eye. Ophthalmology. 93:1986;128-132
104. Maurice D.M., Mishima S. Ocular pharmacokinetics. Sears M.L. Pharmacology of the Eye. 1984;19-116 Springer, New York
105. Milenkovic I., Weick M., Wiedemann P., Reichenbach A., Bringmann A. P2Y receptor-mediated stimulation of Muller glial cell DNA synthesis. dependence on EGF and PDGF receptor transactivation Invest. Ophthalmol. Vis. Sci. 44:2003;1211-1220
106. Mitchell S.M., Membrey W.L., Youle M.S., Obi A., Worrell S., Gazzard B.G. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy. a 2 year prospective study Br. J. Ophthalmol. 83:1999;652-655
107. Miura S., Nishiwaki H., Ieki Y., Hirata Y., Kiryu J., Honda Y. Noninvasive technique for monitoring chorioretinal temperature during transpupillary thermotherapy, with a thermosensitive liposome. Invest. Ophthalmol. Vis. Sci. 44:2003;2716-2721
108. Miyamoto H., Ogura Y., Hashizoe M., Kunou N., Honda Y., Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. 16:1997;930-935
109. Miyamoto H., Kimura H., Yasukawa T., Honda Y., Tabata Y., Ikada Y., Sasai K., Ogura Y. Effect of focal X-ray irradiation on experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 40:1999;1496-1502
110. Morita Y., Ohtori A., Kumura M., Tojo K. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol. Pharm. Bull. 21:1998;188-190
111. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. 32:1991;1785-1790
112. Moritera T., Ogura Y., Yoshimura N., Honda Y., Wada R., Hyon S.H., Ikada Y. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 33:1992;3125-3130
113. Moritera T., Ogura Y., Yoshimura N., Kuriyama S., Honda Y., Tabata Y., Ikada Y. Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres. Curr. Eye Res. 13:1994;171-176
114. Morley M.G., Duker J.S., Ashton P., Robinson M.R. Replacing ganciclovir implants. Ophthalmology. 102:1995;388-392
115. Musch D.C., Martin D.F., Gordon J.F., Davis M.D., Kuppermann B.D. Ganciclovir implant study group. treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant N. Engl. J. Med. 335:1997;83-90
116. Noguchi A., Takahashi T., Yamaguchi T., Kitamura K., Takakura Y., Hashida M., Sezaki H. Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Bioconjugate Chem. 3:1992;132-137
117. Ogawa Y., Okada H., Yamamoto M., Shimamoto T. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic)acids and in vivo degradation of these polymers. Chem. Pharm. Bull. 36:1988;2576-2581
118. Oh H., Takagi H., Takagi C., Suzuma K., Otani A., Ishida K., Matsumura M., Ogura Y., Honda Y. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 40:1999;1891-1898
119. Okabe J., Kimura H., Kunou N., Okabe K., Kato A., Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. 44:2003;740-744
120. Okabe K., Kimura H., Okabe J., Kato A., Kunou N., Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. 44:2003;2702-2707
121. Olsen T.W., Edelhauser H.F., Lim J.I., Geroski D.H. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. 36:1995;1893-1903
122. Otsuji E., Yamaguchi T., Tsuruta H., Yata Y., Nishi H., Okamoto K., Taniguchi K., Kato M., Kotani T., Kitamura K., Takahashi T. Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts. Br. J. Cancer. 73:1996;1178-1182
123. Palestine A.G., Rodrigues M.M., Macher A.M., Chan C.C., Lane H.C., Fauci A.S., Masur H., Longo D., Reichert C.M., Steis R., Rook A.H., Nussenblatt R.B. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 91:1984;1092-1099
124. Patel S.S., Thiagarajan R., Willerson J.T., Yeh E.T. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation. 97:1998;75-81
125. Patey N., Vazeux R., Canioni D., Potter T., Gallatin W.M., Brousse N. Intercellular adhesion molecule-3 on endothelial cells. Expression in tumors but not in inflammatory responses. Am. J. Pathol. 148:1996;465-472
126. Periti P., Mazzei T., Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin. Pharmacokinet. 41:2002;485-504
127. Pertile G., Glaes C. Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am. J. Ophthalmol. 134:2002;560-565
128. Peyman G.A., Khoobehi B., Tawakol M., Schulman J.A., Mortada H.A., Alkan H., Fiscella R. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina. 7:1987;227-229
129. Peyman G.A., Charles H.C., Liu K.R., Khoobehi B., Niesman M. Intravitreal liposome-encapsulated drugs. a preliminary human report Int. Ophthalmol. 12:1988;175-182
130. Pharmacologic Therapy for Macular Degeneration Study Group, 1997. Interferon Alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch. Ophthalmol. 115, 865-872.
131. Pitt C.G., Gratzl M.M., Jeffcoat A.R., Zweidinger R., Schindler A. Sustained drug delivery systems. II. Factors affecting release rates from poly(e-caprolactone) and related biodegradable polymers. J. Pharm. Sci. 68:1979;1534-1538
132. Reiter C., Kakavand B., Rieber E.P., Schattenkirchner M., Riethmuller G., Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum. 34:1991;525-536
133. Retinal Society Terminology Committee, 1983. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90, 121-125.
134. Rettig W.J., Garin-Chesa P., Healey J.H., Su S.L., Jaffe E.A., Old L.J. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. USA. 89:1992;10832-10836
135. Rubsamen P.E., Davis P.A., Hernandez E., O'Grady G.E., Cousins S.W. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. 112:1994;407-413
136. Ryan S.J., Stout J.T., Dugel P.U. Subretinal neovascularization. Ryan S.J. Retina. 1994;1027-1047 Mosby, St. Louis
137. Sakurai E., Ozeki H., Kunou N., Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 33:2001;31-36
138. Sakurai E., Matsuda Y., Ozeki H., Kunou N., Nakajima K., Ogura Y. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. 42:2001;2043-2048
139. Sakurai E., Taguchi H., Anand A., Ambati B.K., Gragoudas E.S., Miller J.W., Adamis A.P., Ambati J. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:2003;2743-2749
140. Sakurai E., Anand A., Ambati B.K., van Rooijen N., Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:2003;3578-3585
141. Sakurai E., Nozaki M., Okabe K., Kunou N., Kimura H., Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Vis. Sci. 44:2003;4845-4852
142. Sanborn G.E., Anand R., Torti R.E., Nightingale S.D., Cal S.X., Yates B., Ashton P., Smith T.J. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch. Ophthalmol. 110:1992;188-195
143. Sanders L.M., Kent J.S., McRae G.I., Vickery B.H., Tice T.R., Lewis D.H. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(D, L-lactide-co-glycolide) microspheres. J. Pharm. Sci. 73:1984;1294-1297
144. Sarraf D., Lee D.A. The role of iontophoresis in ocular drug delivery. J. Ocul. Pharmacol. 10:1994;69-81
145. Sarraf D., Equi R.A., Holland G.N., Yoshizumi M.O., Lee D.A. Transscleral iontophoresis of foscarnet. Am. J. Ophthalmol. 115:1993;748-754
146. Sasai K., Murata R., Mandai M., Takahashi M., Ogura Y., Ngata Y., Nishimura Y., Hiraoka M. Radiation therapy for ocular choroidal neovascularization (phage I/II study). preliminary report Int. J. Radiat. Oncol. Biol. Phys. 39:1997;173-178
147. Scheiffarth O.F., Kampik A., Gunther H., von der Mark K. Proteins of the extracellular matrix in vitreoretinal membranes. Graefes Arch. Clin. Exp. Ophthalmol. 226:1988;357-361
148. Schlingemann R.O., Rietveld F.J., de Waal R.M., Bradley N.J., Skene A.I., Davies A.J., Greaves M.F., Denekamp J., Ruiter D.J. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab. Invest. 62:1990;690-696
149. Scott R.A., Haynes R.J., Orr G.M., Cooling R.J., Pavesio C.E., Charteris D.G. Vitreous surgery in the management of chronic endogenous posterior uveitis. Eye. 17:2003;221-227
150. Shen W.Y., Yu M.J., Barry C.J., Constable I.J., Rakoczy P.E. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularization in the rat. Br. J. Ophthalmol. 82:1998;1063-1071
151. Smith T.J., Pearson P.A., Blandford D.L., Brown J.D., Goins K.A., Hollins J.L., Schmeisser E.T., Glavinos P., Baldwin L.B., Ashton P. Intravitreal sustained-release ganciclovir. Arch. Ophthalmol. 110:1992;255-258
152. Stephenson J. The art of 'HAART'. researchers probe the potential and limits of aggressive HIV treatment JAMA. 277:1997;614-616
153. Tabata Y., Ikada Y. Potentiated in vivo biological activity of basic fibroblast growth factor by incorporation into polymer hydrogel microspheres. Proc. 4th Jpn. Int. SAMPE. Symp. 4:1995;25-28
154. Tabata Y., Ikada Y. Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 31:1998;287-301
155. Tabata Y., Kawai T., Murakami Y., Ikada Y. Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection. Drug Deliv. 4:1997;213-221
156. Tabata Y., Murakami Y., Ikada Y. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Release. 50:1998;123-133
157. Tabata Y., Xi K., Uno K., Ikada Y. Chemical conjugation of interferon with pullulan and its antiviral activity. S. T. P. Pharma. Sci. 9:1999;101-105
158. Tabata Y., Noda Y., Matsui Y., Ikada Y. Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination. J. Control. Release. 59:1999;187-196
159. Tabata Y., Matsui Y., Uno K., Sokawa Y., Ikada Y. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. J. Interferon Res. 19:1999;287-292
160. Taipale J., Keski-Oja J. Growth factors in the extracellular matrix. FASEB J. 11:1997;51-59
161. Tolentino M.J., Husain D., Theodosiadis P., Gragoudas E.S., Gonnolly E., Kahn J., Cleland J., Adamis A.P., Cuthbertson A., Miller J.W. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch. Ophthalmol. 118:2000;78-84
162. Ussery F.M., Gibson S.R., Conklin R.H., Pilot D.F., Stool E.W., Conklin A.J. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology. 95:1988;640-648
163. Veloso A.A. Jr., Zhu Q., Herrero-Vanrell R., Refojo M.F. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. 38:1997;665-675
164. Veronese F.M., Boccu E., Schiavon O., Velo G.P., Conforti A., Franco L., Milanino R. Anti-inflammatory and pharmacokinetic properties of superoxide dismutase derivatized with polyethylene glycol via active esters. J. Pharm. Pharmacol. 35:1983;757-758
165. Vinores S.A., Campochiaro P.A., Conway B.P. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest. Ophthalmol. Vis. Sci. 31:1990;14-28
166. Voigt M., Kralinger M., Kieselbach G., Chapon P., Anagnoste S., Hayden B., Parel J.M. Ocular aspirin distribution. a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration Invest. Ophthalmol. Vis. Sci. 43:2002;3299-3306
167. Vrabec T.R., Baldassano V.F., Whitcup S.M. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology. 105:1998;1259-1264
168. Wada R., Hyon S.H., Ikada Y. Lactic acid oligomer microspheres containing hydrophilic drugs. J. Pharm. Sci. 79:1990;919-924
169. Wada M., Ogata N., Otsuji T., Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr. Eye Res. 18:1999;203-213
170. Xi K., Tabata Y., Uno K., Yoshimoto M., Kishida T., Sokawa Y., Ikada Y. Liver targeting of interferon through pullulan conjugation. Pharm. Res. 13:1996;1846-1850
171. Yamaoka T., Tabata Y., Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J. Pharm. Pharmacol. 47:1995;479-486
172. Yamazaki N., Yuyama H., Nagai M., Ma G.H., Omi S. A comparison of membrane emulsification obtained using SPG (Shirasu Porous Glass) and PTFE [poly(tetrafluoroethylene)] membranes. J. Disper. Sci. Technol. 23:2002;279-292
173. Yang C.S., Khawly J.A., Hainsworth D.P., Chen S.N., Ashton P., Guo H., Jaffe G.J. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 116:1998;69-77
174. Yang C.F., Yasukawa T., Kimura H., Miyamoto H., Honda Y., Tabata Y., Ikada Y., Ogura Y. Experimental corneal neovascularization by basic fibroblast growth factor incorporated into gelatin hydrogel. Ophthalmic Res. 32:2000;19-24
175. Yasukawa T., Kimura H., Tabata Y., Miyamoto H., Honda Y., Ikada Y., Ogura Y. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 40:1999;2690-2696
176. Yasukawa T., Kimura H., Kunou N., Miyamoto H., Honda Y., Ogura Y., Ikada Y. Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch. Clin. Exp. Ophthalmol. 238:2000;186-190
177. Yasukawa T., Kimura H., Tabata Y., Miyamoto H., Honda Y., Ikada Y., Ogura Y. Active drug targeting with immunoconjugates to choroidal neovascularization. Curr. Eye Res. 21:2000;952-961
178. Yasukawa T., Kimura H., Tabata Y., Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52:2001;25-36
179. Yasukawa T., Kimura H., Tabata Y., Miyamoto H., Honda Y., Ogura Y. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 240:2002;672-678
180. Yasukawa T., Kimura H., Tabata Y., Kamizuru H., Miyamoto H., Honda Y., Ogura Y. Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination. Invest. Ophthalmol. Vis. Sci. 43:2002;842-848
181. Yasukawa T., Hoffmann S., Friedrichs U., Eichler W., Wang Y.S., Wiedemann P. A new model of age-related macular degeneration induced by advanced glycation end products. Invest. Ophthalmol. Vis. Sci. 43:2002;S2805
182. Yasukawa T., Hoffmann S., Kacza J., Eichler W., Seeger J., Wiedemann P. Possible role of advanced glycoxidation products accumulated in retinal pigment epithelial cells in the pathology of age-related maculopathy. Invest. Ophthalmol. Vis. Sci. 44:2003;S1698
183. Yoshizumi M.O., Cohen D., Verbukh I., Leinwand M., Kim J., Lee D.A. Experimental transscleral iontophoresis of ciprofloxacin. J. Ocul. Pharmacol. 7:1991;163-167
184. Yoshizumi M.O., Lee D.A., Sarraf D.A., Equi R.A., Verdon W. Ocular toxicity of iontophoretic foscarnet in rabbits. J. Ocul. Pharmacol. Ther. 11:1995;183-189
185. Yoshizumi M.O., Dessouki A., Lee D.A., Lee G. Determination of ocular toxicity in multiple applications of foscarnet iontophoresis. J. Ocul. Pharmacol. Ther. 13:1997;529-536
186. Zhou T., Lewis H., Foster R.E., Schwendeman S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release. 55:1998;281-295